161
|
|
|
NADH:ubiquinone oxidoreductase subunit A12 |
B17.2, DAP13, MC1DN23 |
|
162
|
|
|
NADH:ubiquinone oxidoreductase subunit A13 |
B16.6, CDA016, CGI-39, GRIM-19, GRIM19, MC1DN28 |
|
163
|
|
|
NADH:ubiquinone oxidoreductase subunit A2 |
B8, CD14, CIB8, MC1DN13 |
|
164
|
|
|
NADH:ubiquinone oxidoreductase subunit A3 |
B9, CI-B9 |
|
165
|
|
|
NADH:ubiquinone oxidoreductase subunit A6 |
B14, CI-B14, LYRM6, MC1DN33, NADHB14 |
|
166
|
|
|
NADH:ubiquinone oxidoreductase subunit A8 |
CI-19KD, CI-PGIV, MC1DN37, PGIV |
|
167
|
|
|
NADH:ubiquinone oxidoreductase subunit A9 |
CC6, CI-39k, CI39k, COQ11, MC1DN26, NDUFS2L, SDR22E1 |
|
168
|
|
|
NADH:ubiquinone oxidoreductase subunit AB1 |
ACP, ACP1, FASN2A, SDAP |
|
169
|
|
|
NADH:ubiquinone oxidoreductase complex assembly factor 1 |
CGI-65, CGI65, CIA30, MC1DN11 |
|
170
|
|
|
NADH:ubiquinone oxidoreductase complex assembly factor 2 |
B17.2L, MC1DN10, MMTN, NDUFA12L, mimitin |
Alzheimer disease, Attention deficit hyperactivity disorder, Brain disease, Cannabis abuse, Cockayne syndrome, Leigh syndrome, Mitochondrial complex deficiency, Mitochondrial disease, Parkinson disease, Schizophrenia, Scoliosis, Substance abuse, Uv-sensitive syndrome |